Catherine Mattes is a Partner in Quinn Emanuel’s New York office. Ms. Mattes’ practice primarily focuses on complex litigation in the chemical, pharmaceutical, and biotechnology areas. Ms. Mattes has extensive experience in patent litigation and counseling in a broad range of technologies. She has experience in all stages of patent litigation, including pre-suit investigation, fact and expert discovery, trial, post-trial, and appeals. Ms. Mattes has represented innovative brand name pharmaceutical companies in complex Hatch-Waxman litigations against multiple defendants.
Her recent representations include litigations concerning: Invokana®/Invokamet® (a treatment for type II diabetes); Abraxane® (a treatment for pancreatic and breast cancers); Omeprazole OTC (a treatment for heartburn); NuvaRing® (a contraceptive treatment); Revlimid® (a treatment for multiple myeloma and myelodysplastic syndromes); Nuedexta® (a treatment for pseudobulbar affect); and Xyrem® (a treatment for excessive daytime sleepiness and cataplexy in patients with narcolepsy).
Ms. Mattes’ practice also includes counseling clients regarding patent portfolio evaluation, including conducting diligences regarding the patentability of inventions, the validity of patents and the freedom to operate new technologies. Her practice also involves the negotiation and preparation of licensing and settlement agreements.
Ms. Mattes received her J.D. from Brooklyn Law School, where she interned with Magistrate Judge Kevin Fox and District Court Judge Alvin Hellerstein in the Southern District of New York. She performed graduate-level research and earned a M.S. in Biomedical Engineering from Columbia University in 2006. She earned a B.S. in Biological and Environmental Engineering from Cornell University in 2005.
- Janssen Pharmaceuticals, Inc.
- Mitsubishi Tanabe Pharma
- Merck & Co.
- Takeda Pharmaceuticals USA, Inc..
- Chiesi Pharmaceuticals, Inc.
- AbCellera Biologics, Inc.
- Avanir Pharmaceuticals, Inc.
- Celgene Corporation
Representing Janssen Pharmaceutical and Mitsubishi Tanabe Pharma in a fourteen-defendant Hatch-Waxman litigation relating to Janssen’s Invokana/Invokamet/Invokamet XR drug products, which are indicated for the treatment of diabetes. All of the actions settled favorably for Janssen and MTPC.
Represented Merck in multiple Hatch-Waxman litigations relating to Merck’s NuvaRing® product. The Federal Circuit ruled in favor of Merck in 2017.
Represented Celgene Corporation in multiple Hatch-Waxman actions relating to its Abraxane® (paclitaxel protein-bound particles) drug product for the treatment of breast cancer, pancreatic cancer, and non-small cell lung cancer. The first-filer action settled favorably for Celgene.
Represented Avanir Pharmaceuticals, Inc. in multiple Hatch-Waxman actions relating to its Nuedexta® (quinidine/dextromethorphan) drug product. Obtained trial victory in favor of Avanir, finding infringement and upholding the validity of Avanir’s patents for twelve years through 2026. The district court’s opinion was upheld by the Federal Circuit in August 2015 by a unanimous Rule 36 affirmance.
- Brooklyn Law School
- Columbia University
(M.S., Biomedical Engineering, 2006)
- Cornell University
(B.S., Biological and Environmental Engineering, 2005)
- The State Bar of New York
- The State Bar of New Jersey
- United States Court of Appeals:
- Federal Circuit
- Registered to Practice Before the United States Patent and Trademark Office
- Recognized by The Best Lawyers in America as Ones to Watch, 2021-2023
- Recognized by The Best Lawyers in America as Ones to Watch, “Women in the Law", 2022